Stefan Blochlinger

Showing 1-2 of 2 articles

Coronary interventions

Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents for primary percutaneous coronary revascularisation of acute myocardial infarction

Pilgrim T, Piccolo R, Heg D, Roffi M, Tüller D, Vuilliomenet A, Mueller O, Cook S, Weilenmann D, Kaiser C, Jamshidi P, Khattab A, Taniwaki M, Rigamonti F, Nietlispach F, Blochlinger S, Wenaweser P, Jüni P, Windecker S

December 9, 2016 | 10.4244/EIJY15M12_09

Predictors of adverse events among patients undergoing primary percutaneous coronary intervention: insights from a pooled analysis of the COMFORTABLE AMI and EXAMINATION trials

Taniwaki M, Stefanini G, Räber L, Brugaletta S, Cequier A, Heg D, Iñiguez A, Kelbæk H, Serra A, Ostojic M, Hernández-Antolín R, Baumbach A, Blochlinger S, Jüni P, Mainar V, Sabate M, Windecker S

August 20, 2015 | 10.4244/EIJY14M07_12

1

Latest news

Atherectomies, in-stent restenosis, stent thrombosis, coronary physiology in TAVI and heart failure

Ahead of print: New technique of percutaneous mitral valvuloplasty

C. Aurigemma et al

Rotational atherectomy and the myth of Sisyphus

TICAKOREA, PEPCAD NSTEMI, CROSS-AMI, PARTNER-2A 5 years, and more

(The Trials book is supported by Biotronik)

Guidance Papers

Guidelines, consensus & position papers

Fractional flow reserve substitutes in aortic stenosis

Nils P. Johnson

This Week's JAA's: Real-world Use of the Evolut PRO Valve...

Valvular disease